Camrelizumab + Apatinib for Highrisk Chemorefractory or Relapsed Gestational Trophoblastic Neoplasia
1 ビュー
• 06/30/23
0
0
埋め込む
administrator
加入者
Warm Welcome to the latest OncoShorts podcast, brought to you by MedSynapse. OncoShorts covers a wide range of clinical and scientific medical content, that offers enriching insights into the World of Oncology.
In today’s podcast episode, we will discuss details of a randomized phase 2 trial, titled, Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia, featured in the November 2021 Issue of The Lancet Oncology.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント